RxSight (RXST) Investor presentation summary

Vision and product innovation

• Aims to transform cataract surgery outcomes through lens adjustability, enabling targeted refractive accuracy and customization to patient lifestyle.

• Adjustable IOLs deliver unmatched refractive precision, with LAL eyes showing 14.5 times better odds of optimal visual outcomes compared to other lenses.

• Developing a suite of adjustable IOLs, including next-generation and toric models, with future products leveraging adjustability for enhanced vision and workflow.

Clinical data and patient outcomes

• Real-world data from over 7,000 eyes shows more than 94% achieve +/- MRSE 1 and over 90% reach 20/25 distance and J2 near vision without glasses.

• 90% of surveyed users believe LAL provides the highest quality of vision, and 79% would choose it for their own premium IOL surgery.

Market strategy and global expansion

• Products are approved in 10 markets across North America, Europe, and Asia-Pacific, with a focus on top premium IOL markets.

• Employs a direct model in high-volume markets and hybrid models elsewhere, targeting early adopters and key opinion leaders.